Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL874274 | 0.91 | MMP2 (0.48) | GPR139SMN1; SMN2MAPTKMT2AHTT | |
| SCHEMBL876948 | 0.87 | MAPK10 (0.43) | GPR139SMN1; SMN2KMT2AHTTMEN1 | |
| SCHEMBL878420 | 0.86 | KMT2A (0.45) | SMN1; SMN2MAPTKMT2AHTTMEN1 | |
| SCHEMBL877953 | 0.85 | LMNA (0.48) | SMN1; SMN2KMT2AMEN1ALDH1A1HSD17B10 | |
| SCHEMBL875318 | 0.83 | KMT2A (0.46) | GPR139SMN1; SMN2MAPTKMT2AHTT | |
| SCHEMBL878087 | 0.82 | SMN1; SMN2 (0.46) | SMN1; SMN2KMT2AMEN1ALDH1A1HSD17B10 | |
| SCHEMBL874237 | 0.80 | SMN1; SMN2 (0.53) | GPR139SMN1; SMN2MAPTKMT2AHTT | |
| SCHEMBL874772 | 0.79 | KMT2A (0.47) | GPR139KMT2AHTTMEN1ALDH1A1 | |
| SCHEMBL877932 | 0.79 | KMT2A (0.47) | KMT2AHTTMEN1ALDH1A1HSD17B10 | |
| SCHEMBL874492 | 0.78 | KMT2A (0.49) | KMT2AHTTMEN1ALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140148459-A1 | MATRIX METALLOPROTEINASE INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2014-05-29 | — | — | US | disclosed |
| EP-2619185-A1 | MATRIX METALLOPROTEINASE INHIBITORS | Ranbaxy Laboratories Limited (IN) | 2013-07-31 | — | — | EP | disclosed |
| WO-2012038942-A1 | MATRIX METALLOPROTEINASE INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2012-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140148459-A1 | MATRIX METALLOPROTEINASE INHIBITORS | MMP9, MMP12, MMP10 | GPR139 2694/4885SMN1; SMN2 3367/4885MAPT 2663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.